Why Humacyte (HUMA) Stock Is Falling Sharply

Humacyte Inc HUMA shares are trading lower by 29% to $2.04 during Wednesday’s session after the company priced a $50 million public offering of 25 million common shares at $2.00 per share.

What To Know: Humacyte late Tuesday priced its public offering of 25 million shares of its common stock at $2.00 per share, aiming to raise $50 million before expenses. The offering is set to close on March 27, pending customary conditions. Underwriters have a 30-day option to purchase an additional 3.75 million shares.

TD Cowen, Barclays and BTIG are leading the offering, with H.C. Wainwright & Co. and The Benchmark Company acting as lead managers. Proceeds will support the commercialization of SYMVESS™ for vascular trauma, pipeline development and general corporate needs.

Humacyte will also release its financial results for the fourth quarter and year ended December 31, 2024, on Friday.

Read Also: GameStop Stock Is Surging Wednesday: What’s Going On?

How To Buy HUMA Stock

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Humacyte’s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

According to data from Benzinga Pro, HUMA has a 52-week high of $9.97 and a 52-week low of $1.99.